2,300,000 Common Stock of Aclaris Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2017.
January 15, 2017
Share
2,300,000 Common Stock of Aclaris Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2017. These Common Stock will be under lockup for 60 days starting from 17-NOV-2016 to 16-JAN-2017.
Details:
The company directors and executive officers have agreed that, they will not without the prior written consent of Jefferies LLC and Leerink Partners LLC, sell, offer to sell, contract to sell or lend any shares or related securities, affect any short sale, for a period of 90 days after the date of this prospectus supplement. One of the stockholders, Sofinnova Venture Partners VIII, L.P., has agreed to this restriction for a period of 60 days.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
ACLARIS THERAPEUTICS, INC. 
